WednesdayOct 04, 2023 2:59 pm

BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination

Estrella Immunopharma (NASDAQ: ESLA, ESLAW), formerly known as TradeUP Acquisition Corp. (“UPTD”), has successful closed a business combination with Estrella Biopharma Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company focused on developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. According to the announcement, shares in the combined company — Estrella Immunopharma — began trading on Oct. 2, 2023; in addition, all remaining UPTD units will separate into their underlying components, consisting of one share of combined company's common stock and one-half of one warrant. The combined company brings together capital and a…

Continue Reading

WednesdayOct 04, 2023 2:12 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Dismissal of Motion, Wins $2.8 Million Award

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting on the status of court action filed against it. The company announced that the Ontario Superior Court of Justice dismissed the motion to set aside an arbitration award to FSD Pharma; the motion was filed by Dr. Raza Bokhari, former FSD Pharma CEO of FSD Pharma and current CEO of Medicus Pharma Ltd. In addition, the company noted an earlier decision by the Honourable J. Douglas…

Continue Reading

WednesdayOct 04, 2023 1:59 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference

Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston. The Acclaim-1 Phase 1 study results have demonstrated the safety and efficacy of REQORSA(R) in combination with Tagrisso(R), bringing hope to patients with late-stage NSCLC. Moreover, preclinical studies have highlighted REQORSA(R)'s potential in combination with a checkpoint inhibitor to combat chemotherapy-resistant small cell lung…

Continue Reading

WednesdayOct 04, 2023 11:50 am

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) to Present at Upcoming Dawson James Conference

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that it will present at the 8th Annual Dawson James Conference taking place at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida, on Thursday, Oct. 12, 2023. NextPlat Corp’s executive chairman and CEO Charles M. Fernandez will deliver the company’s presentation and conduct in-person, one-on-one meetings throughout the conference. Fernandez’s presentation is slated to begin at 11 a.m. ET in Preserve Ballroom C. To view the full press release, visit https://ibn.fm/3eEUL About NextPlat Corp. NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors…

Continue Reading

WednesdayOct 04, 2023 10:23 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at CPHI Barcelona 2023, Other Upcoming Events

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced that it will showcase its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place Oct. 24 to 26. Scinai’s CDMO offers upstream and downstream process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing including aseptic filling to biopharmaceutical and biotech clients. According to the announcement, several members of Scinai’s executive leadership team will be available to meet with potential partners and clients of the company’s end-to-end biologics CDMO service. Interested parties may request one-to-one meetings through the CPHI partnering platform, accessible to participants…

Continue Reading

MondayOct 02, 2023 2:17 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Releases Shareholder Letter Regarding Agreement to Combine with Leading AI Company

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a shareholder letter from Renovaro CEO Mark R. Dybul, MD. In the letter, Dybul provides information about the definitive agreement the company recently signed with artificial intelligence company GEDiCube. In the letter, Dybul noted that the two companies decided to combine in order to accelerate a shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics. Dybul noted that he anticipates serving as…

Continue Reading

FridaySep 29, 2023 4:03 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the financial results for its fiscal year 2023, the period ending June 30, 2023. In addition, the company provided a status update on its pharmaceutical drug-development programs as well as the commercial segment for BayMedica LLC, its wholly owned subsidiary. Highlights of the report include total sales for subsidiary BayMedica of rare cannabinoids in the health and wellness sector reaching $4.1 million, an increase of 280% over the previous fiscal year and $2.3 million in revenue for…

Continue Reading

FridaySep 29, 2023 2:00 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked a deal with GEDi Cube Intl Ltd. The agreement is to combine the two companies with GEDi Cube becoming a wholly owned subsidiary of Renovaro in a stock-for-stock acquisition. The combined company would focus on accelerating precision and personalized medicine for longevity powered by mutually reinforcing artificial intelligence (“AI”) and biotechnology platforms to enable early diagnosis, better targeted treatments and drug discovery. GEDi Cube is an artificial intelligence medical technology company. According…

Continue Reading

ThursdaySep 28, 2023 1:26 pm

BioMedNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Partners with IBN for Corporate Communications Initiatives

SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, IBN will leverage its suite of communications solutions to generate greater awareness of SenesTech, a company focused on developing effective pest-control solutions that are grounded in science and proven through field testing. IBN brings an array of communication channels to the new partnership, including an investor-based distribution network of more than 5,000 key syndication outlets,…

Continue Reading

ThursdaySep 28, 2023 11:51 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050